(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Car T Cell Therapy For Multiple Myeloma pipeline constitutes 5+ key companies continuously working towards developing 5+ Car T Cell Therapy For Multiple Myeloma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Car T Cell Therapy For Multiple Myeloma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Car T Cell Therapy For Multiple Myeloma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Car T Cell Therapy For Multiple Myeloma Market.
Some of the key takeaways from the Car T Cell Therapy For Multiple Myeloma Pipeline Report:
- Companies across the globe are diligently working toward developing novel Car T Cell Therapy For Multiple Myeloma treatment therapies with a considerable amount of success over the years.
- Car T Cell Therapy For Multiple Myeloma companies working in the treatment market are Cartesian Therapeutics, Arcellx, Novartis, Bristol-Myers Squibb, CARsgen Therapeutics, Poseida Therapeutics, Juno Therapeutics, CRISPR Therapeutics, bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics, Celyad Oncology, Allogene Therapeutics, Gadeta, Nanjing IASO Biotherapeutics, and others, are developing therapies for the Car T Cell Therapy For Multiple Myeloma treatment
- Emerging Car T Cell Therapy For Multiple Myeloma therapies in the different phases of clinical trials are- Descartes-11, CART-ddBCMA, PHE885, Orvacabtagene Autoleucel, Zevorcabtagene autoleucel (zevor-cel or CT053), P-BCMA-ALLO1, CC-95266, Fully human BCMA chimeric antigen receptor autologous T-cell injection (CT103A), CTX120, CC-98633, bb21217, UCARTCS1A, CB-011, LMY-920, CYAD-211, ALLO-715 ± Nirogacestat, TEG002, CAR-T (CAR-GPRC5D), and others are expected to have a significant impact on the Car T Cell Therapy For Multiple Myeloma market in the coming years.
- In January 2023, CARsgen Therapeutics has entered into a partnership with Huadong Medicine for the commercialization of zevorcabtageneautoleucel (zevor-cel), also known as CT053, in mainland China. CT053, developed by CARsgen, is a fully human, autologous BCMA CAR T-cell product designed for the treatment of relapsed/refractory multiple myeloma (R/R MM). This therapeutic candidate involves genetically modifying autologous T cells with a CAR containing a complete human anti-BCMA single-chain fragment variant, ensuring a high binding affinity. As part of the collaboration, Huadong Medicine gains exclusive rights for the commercialization of CARsgen’s CT053 in mainland China. The agreement includes an upfront payment of $29.7 million (RMB 200 million) to CARsgen, with the potential for additional payments of up to $152.4 million (RMB 1,025 million) based on regulatory and commercial milestones. CARsgen will retain responsibility for the development, regulatory approval, and production of CT053 in the country.
- In December 2022, CARsgen Therapeutics Holdings Limited revealed that during the 2022 American Society of Hematology (ASH) Annual Meeting, the company showcased a poster featuring outcomes from the phase I/II LUMMICAR STUDY 1 clinical trial of zevorcabtagene autoleucel, also known as zevor-cel (R&D code: CT053). This autologous CAR T-cell product candidate, targeting BCMA, was evaluated in Chinese patients experiencing relapsed/refractory multiple myeloma (R/R MM).
Car T Cell Therapy For Multiple Myeloma Overview
Chimeric Antigen Receptor T-cell (CAR-T) therapy for Multiple Myeloma is an innovative and personalized immunotherapy approach designed to treat multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. In CAR-T therapy, a patient’s own T cells (a type of immune cell) are extracted from their blood and genetically modified to express a chimeric antigen receptor (CAR) on their surface.
Get a Free Sample PDF Report to know more about Car T Cell Therapy For Multiple Myeloma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/car-t-cell-therapy-for-multiple-myeloma-pipeline-insight
Emerging Car T Cell Therapy For Multiple Myeloma Drugs Under Different Phases of Clinical Development Include:
- Descartes-11: Cartesian Therapeutics
- CART-ddBCMA: Arcellx
- PHE885: Novartis
- Orvacabtagene Autoleucel: Bristol-Myers Squibb
- Zevorcabtagene autoleucel (zevor-cel or CT053): CARsgen Therapeutics
- P-BCMA-ALLO1: Poseida Therapeutics
- CC-95266: Juno Therapeutics
- Fully human BCMA chimeric antigen receptor autologous T-cell injection (CT103A): Nanjing IASO Biotherapeutics
- CTX120: CRISPR Therapeutics
- CC-98633: Juno Therapeutics
- bb21217: bluebird bio
- UCARTCS1A: Cellectis SA
- CB-011: Caribou Biosciences
- LMY-920: Luminary Therapeutics
- CYAD-211: Celyad Oncology
- ALLO-715 ± Nirogacestat: Allogene Therapeutics
- TEG002: Gadeta
- CAR-T (CAR-GPRC5D): Nanjing IASO Biotherapeutics
Car T Cell Therapy For Multiple Myeloma Route of Administration
Car T Cell Therapy For Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Subcutaneous
- Intravenous
- Oral
- Intramuscular
- Molecule Type
Car T Cell Therapy For Multiple Myeloma Molecule Type
Car T Cell Therapy For Multiple Myeloma Products have been categorized under various Molecule types, such as
- Small molecules
- Natural metabolites
- Monoclonal antibodies
- Product Type
Car T Cell Therapy For Multiple Myeloma Pipeline Therapeutics Assessment
- Car T Cell Therapy For Multiple Myeloma Assessment by Product Type
- Car T Cell Therapy For Multiple Myeloma By Stage and Product Type
- Car T Cell Therapy For Multiple Myeloma Assessment by Route of Administration
- Car T Cell Therapy For Multiple Myeloma By Stage and Route of Administration
- Car T Cell Therapy For Multiple Myeloma Assessment by Molecule Type
- Car T Cell Therapy For Multiple Myeloma by Stage and Molecule Type
DelveInsight’s Car T Cell Therapy For Multiple Myeloma Report covers around 5+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Car T Cell Therapy For Multiple Myeloma product details are provided in the report. Download the Car T Cell Therapy For Multiple Myeloma pipeline report to learn more about the emerging Car T Cell Therapy For Multiple Myeloma therapies
Some of the key companies in the Car T Cell Therapy For Multiple Myeloma Therapeutics Market include:
Key companies developing therapies for Car T Cell Therapy For Multiple Myeloma are – CARsgen Therapeutics, Poseida Therapeutics, Juno Therapeutics, CRISPR Therapeutics, bluebird bio, Cellectis SA, Caribou Biosciences, Celyad Oncology, Allogene Therapeutics, Gadeta, Nanjing IASO Biotherapeutics, and others.
Car T Cell Therapy For Multiple Myeloma Pipeline Analysis:
The Car T Cell Therapy For Multiple Myeloma pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Car T Cell Therapy For Multiple Myeloma with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Car T Cell Therapy For Multiple Myeloma Treatment.
- Car T Cell Therapy For Multiple Myeloma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Car T Cell Therapy For Multiple Myeloma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Car T Cell Therapy For Multiple Myeloma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Car T Cell Therapy For Multiple Myeloma drugs and therapies
Car T Cell Therapy For Multiple Myeloma Pipeline Market Drivers
- Increasing prevalence of Multiple Myeloma, increase in technological advancement of CAR T-cell manufacturing in myeloma are some of the important factors that are fueling the Car T Cell Therapy For Multiple Myeloma Market.
Car T Cell Therapy For Multiple Myeloma Pipeline Market Barriers
- However, high cost associated with the treatment, poor persistence of CAR T cells and other factors are creating obstacles in the Car T Cell Therapy For Multiple Myeloma Market growth.
Scope of Car T Cell Therapy For Multiple Myeloma Pipeline Drug Insight
- Coverage: Global
- Key Car T Cell Therapy For Multiple Myeloma Companies: Cartesian Therapeutics, Arcellx, Novartis, Bristol-Myers Squibb, CARsgen Therapeutics, Poseida Therapeutics, Juno Therapeutics, CRISPR Therapeutics, bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics, Celyad Oncology, Allogene Therapeutics, Gadeta, Nanjing IASO Biotherapeutics, and others
- Key Car T Cell Therapy For Multiple Myeloma Therapies: Descartes-11, CART-ddBCMA, PHE885, Orvacabtagene Autoleucel, Zevorcabtagene autoleucel (zevor-cel or CT053), P-BCMA-ALLO1, CC-95266, Fully human BCMA chimeric antigen receptor autologous T-cell injection (CT103A), CTX120, CC-98633, bb21217, UCARTCS1A, CB-011, LMY-920, CYAD-211, ALLO-715 ± Nirogacestat, TEG002, CAR-T (CAR-GPRC5D), and others
- Car T Cell Therapy For Multiple Myeloma Therapeutic Assessment: Car T Cell Therapy For Multiple Myeloma current marketed and Car T Cell Therapy For Multiple Myeloma emerging therapies
- Car T Cell Therapy For Multiple Myeloma Market Dynamics: Car T Cell Therapy For Multiple Myeloma market drivers and Car T Cell Therapy For Multiple Myeloma market barriers
Request for Sample PDF Report for Car T Cell Therapy For Multiple Myeloma Pipeline Assessment and clinical trials
Table of Contents
1. Car T Cell Therapy For Multiple Myeloma Report Introduction
2. Car T Cell Therapy For Multiple Myeloma Executive Summary
3. Car T Cell Therapy For Multiple Myeloma Overview
4. Car T Cell Therapy For Multiple Myeloma- Analytical Perspective In-depth Commercial Assessment
5. Car T Cell Therapy For Multiple Myeloma Pipeline Therapeutics
6. Car T Cell Therapy For Multiple Myeloma Late Stage Products (Phase II/III)
7. Car T Cell Therapy For Multiple Myeloma Mid Stage Products (Phase II)
8. Car T Cell Therapy For Multiple Myeloma Early Stage Products (Phase I)
9. Car T Cell Therapy For Multiple Myeloma Preclinical Stage Products
10. Car T Cell Therapy For Multiple Myeloma Therapeutics Assessment
11. Car T Cell Therapy For Multiple Myeloma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Car T Cell Therapy For Multiple Myeloma Key Companies
14. Car T Cell Therapy For Multiple Myeloma Key Products
15. Car T Cell Therapy For Multiple Myeloma Unmet Needs
16 . Car T Cell Therapy For Multiple Myeloma Market Drivers and Barriers
17. Car T Cell Therapy For Multiple Myeloma Future Perspectives and Conclusion
18. Car T Cell Therapy For Multiple Myeloma Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Car T Cell Therapy For Multiple Myeloma Pipeline Drugs Analysis Report: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | CARsgen Therapeutics, Poseida Therapeutics, Juno
